ALNYLAM PHARMACEUTICALS, INC. Federal Income Tax Expense (Benefit), Continuing Operations
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Federal Income Tax Expense (Benefit), Continuing Operations of -$40.21 million for the 12-month period ending 2014-12-31, per its 10-K filed 2017-02-15.
Discontinued › Expense Statement › Income Tax
us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations · last filed 2017-02-15
- ALNYLAM PHARMACEUTICALS, INC. federal income tax expense (benefit), continuing operations for fiscal 2014 was -$40.21M.
- ALNYLAM PHARMACEUTICALS, INC. federal income tax expense (benefit), continuing operations for fiscal 2013 was -$2.66M.
- ALNYLAM PHARMACEUTICALS, INC. federal income tax expense (benefit), continuing operations for fiscal 2012 was -$10.52M, a 20330.77% decline from fiscal 2011.
- ALNYLAM PHARMACEUTICALS, INC. federal income tax expense (benefit), continuing operations for fiscal 2011 was $52.00K, a 90.81% decline from fiscal 2010.
| Period end | Federal Income Tax Expense (Benefit), Continuing Operations 12 month |
|---|---|
| 2014-12-31 | -$40.21M 10-K · filed 2017-02-15 |
| 2013-12-31 | -$2.66M 10-K · filed 2016-02-12 |
| 2012-12-31 | -$10.52M 10-K · filed 2015-02-13 |
| 2011-12-31 | $52.00K 10-K · filed 2014-02-20 |
| 2010-12-31 | $566.00K 10-K · filed 2013-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |